Century Therapeutics, Inc.

As of August 14, 2025, Century Therapeutics, Inc. shows a mildly bearish technical trend with mixed signals from various indicators, having significantly underperformed the S&P 500 with a year-to-date decline of 49.8%.

As of May 16, 2022, Century Therapeutics, Inc. is considered risky and overvalued, with poor financial metrics and a year-to-date return of -49.8%, significantly underperforming the S&P 500's gain of 12.22%.

As of May 16, 2022, Century Therapeutics, Inc. is rated as risky and overvalued, with a price-to-book ratio of 0.22, an EV to EBITDA of 6.45, and a negative ROE of -7.99%, significantly underperforming the S&P 500 with a year-to-date decline of 43.07%.

As of June 13, 2025, the market trend is mildly bearish, influenced by daily moving averages, while weekly indicators show mixed signals and overall performance has been notably negative compared to the S&P 500 over the past few years.

Century Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $109 million and a net profit of $77 million as of March 2025. It has a market cap of $50.94 million, with key metrics indicating it is currently loss-making and does not pay dividends.

As of Jun 18, Century Therapeutics, Inc. has a market capitalization of 50.94 million and reported net sales of 114.89 million with a net profit of -21.95 million over the last four quarters. Shareholder's funds are 161.36 million, and total assets amount to 353.22 million.